Use of ketamine in patients with multifactorial neuropathic pain: a systematic review and meta-analysis

Vista sencilla de ítem
dc.contributor.authorBruna Mejias, Alejandro
dc.contributor.authorBaeza, Vicente
dc.contributor.authorGamboa, Javiera
dc.contributor.authorBaez Flores, Belén
dc.contributor.authorSan Martin, Jessica
dc.contributor.authorAstorga, Constanza
dc.contributor.authorLeyton, Javiera
dc.contributor.authorNova Baeza, Pablo
dc.contributor.authorOrellana-Donoso, Mathias
dc.contributor.authorSuazo Santibañez, Alejandra
dc.contributor.authorBecerra Farfán, Álvaro
dc.contributor.authorOyanedel Amaro, Gustavo
dc.contributor.authorValenzuela Fuenzalida, Juan José
dc.date.accessioned2025-03-19T18:35:52Z
dc.date.available2025-03-19T18:35:52Z
dc.date.issued2024-09-03
dc.description.abstractNeuropathic pain (NP) is a heterogeneous group of conditions characterized by the experience of a number of sensory disturbances including pain, burning sensations, paroxysms of stabbing pain, dysesthesias, allodynia, and hyperalgesia. The above-mentioned sensations may occur in a specific dermatome area or other delimited region of the body. The objective of this review was to analyze the evidence for ketamine in multifactorial neuropathic pain. The research group systematically searched the databases MEDLINE (via PubMed), EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature (Cinahl), and the Web of Science. The findings of this review show that different forms of low doses of ketamine (LDK) do not present statistically significant changes for any of the scales included. In this study, the total symptom score [standardized mean difference (SMD) = -3.59, confidence interval (CI) = -4.16 to -3.02, and p < 0.00001], neuropathy impairment score (SMD = -1.42, CI = -3.68 to 0.84, and p = 0.22), and neuropathy symptom checklist (SMD = -0.09, CI = -0.15 to -0.02, and p = 0.01) were taken into account. For finality compared to the use of a placebo, the findings suggest that LDK does not exhibit significant differences in terms of pain reduction and functionality. Moreover, no specific dosages are identified to support the use of LDK in the reduction in NP.
dc.identifier.citationPharmaceuticals, Vol. 17, N°9, 1165 (2024) p.1-15
dc.identifier.doihttps://doi.org/10.3390/ph17091165
dc.identifier.issne1424-8247
dc.identifier.orcidhttps://orcid.org/0000-0002-1781-062X
dc.identifier.urihttp://hdl.handle.net/20.500.12254/4063
dc.language.isoen
dc.publisherMDPI
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectKetamine
dc.subjectPharmacology
dc.subjectNeuropathic pain
dc.subjectPolyneuropathy
dc.titleUse of ketamine in patients with multifactorial neuropathic pain: a systematic review and meta-analysis
dc.typeArticle
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
pharmaceuticals-17-01165-v2.pdf
Tamaño:
1.54 MB
Formato:
Adobe Portable Document Format
Descripción:
Texto completo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
347 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Artículos de Revistas